481 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
REGN Regeneron Pharmaceuticals, Inc. $386.665 $41.78B N/A
Article Searches
Implied Volatility Surging for Regeneron (REGN) Stock Options http://www.zacks.com/stock/news/432100/implied-volatility-surging-for-regeneron-regn-stock-options?cid=CS-ZC-FT-432100 Jun 20, 2019 - Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676 Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Alnylam Completes Enrollment in Phase III Study of Lumasiran http://www.zacks.com/stock/news/431112/alnylam-completes-enrollment-in-phase-iii-study-of-lumasiran?cid=CS-ZC-FT-431112 Jun 18, 2019 - Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate http://www.zacks.com/stock/news/430443/regeneron-regn-presents-positive-data-on-lymphoma-candidate?cid=CS-ZC-FT-430443 Jun 17, 2019 - Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Alnylam Completes Rolling NDA Submission to FDA for Givosiran http://www.zacks.com/stock/news/425850/alnylam-completes-rolling-nda-submission-to-fda-for-givosiran?cid=CS-ZC-FT-425850 Jun 06, 2019 - Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909 Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service http://www.zacks.com/research-daily/418566/top-analyst-reports-for-home-depot-phillip-morris-united-parcel-service?cid=CS-ZC-FT-418566 May 23, 2019 - Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study http://www.zacks.com/stock/news/417074/adverum-up-as-fda-lifts-hold-on-cohort-of-wet-amd-study?cid=CS-ZC-FT-417074 May 20, 2019 - Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates http://www.zacks.com/stock/news/414511/biotech-stock-roundup-fda-nod-for-regns-eylea-in-dr-tie-ups-other-updates?cid=CS-ZC-FT-414511 May 15, 2019 - Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.

Pages: 123456...49

Page 1>